197 | CD4+ T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP

Documenti analoghi

• 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY
  di: M. S. Topp, et al.
  Pubblicazione: (2025)
• 631 | EFFICACY OF POLA‐R‐CHP IN PREVIOUSLY UNTREATED CD5‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA
  di: J. Sui, et al.
  Pubblicazione: (2025)
• 650 | EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL: A RETROSPECTIVE ANALYSIS OF REAL‐WORLD DATA
  di: S. Yang, et al.
  Pubblicazione: (2025)
• 290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY
  di: N. Nakamura, et al.
  Pubblicazione: (2025)
• 627 | PROMISING OUTCOMES WITH POLA‐R‐CHP IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA WITH BULKY DISEASE
  di: Z. Jiang, et al.
  Pubblicazione: (2025)